Evidence map›Paper›PMID 29076047›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018

Tetracycline use in the community may promote decreased susceptibility to quinolones in Escherichia coli isolates.

E Batard, M-A Vibet, S Thibaut, S Corvec, J Pivette, D Lepelletier, J Caillon, E Montassier

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Relationship between Antibiotic Consumption and Resistance: A Systematic Review.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

E BatardMicrobiotas Hosts Antibiotics bacterial Resistances (MiHAR) Lab, Institut de Recherche en Santé 2 (IRS2), Université de Nantes, 22 Boulevard Benoni-Goullin, 44200, Nantes, France. eric.batard@univ-nantes.fr.
M-A VibetLaboratoire de Mathématiques Jean Leray, Université de Nantes, Nantes, France.
S ThibautMedqual, Centre Ressource en Antibiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.
S CorvecBacteriology and Infection Control, Centre Hospitalier Universitaire de Nantes, Nantes, France.
J PivetteMedical Department, French Health Insurance Scheme, Nantes, France.
D LepelletierMicrobiotas Hosts Antibiotics bacterial Resistances (MiHAR) Lab, Institut de Recherche en Santé 2 (IRS2), Université de Nantes, 22 Boulevard Benoni-Goullin, 44200, Nantes, France.
J CaillonMedqual, Centre Ressource en Antibiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.
E MontassierMicrobiotas Hosts Antibiotics bacterial Resistances (MiHAR) Lab, Institut de Recherche en Santé 2 (IRS2), Université de Nantes, 22 Boulevard Benoni-Goullin, 44200, Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously found that the hospital use of tetracyclines is associated with quinolone resistance in hospital isolates of Enterobacteriaceae. Tetracyclines are heavily used in the community. Our aim was to assess whether their use in the community favors quinolone resistance in community isolates of Escherichia coli. Monthly data of community antibiotics use and E. coli quinolone resistance in a 1.3 million inhabitant French area were obtained from 2009 to 2014, and were analyzed with autoregressive integrated moving average (ARIMA) models. Quinolone use decreased from 10.1% of the total antibiotic use in 2009 to 9.3% in 2014 (trend, - 0.016; p-value < 0.0001), while tetracycline use increased from 16.5% in 2009 to 17.1% in 2014 (trend, 0.016; p < 0.0001). The mean (95% confidence interval) monthly proportions of isolates that were non-susceptible to nalidixic acid and ciprofloxacin were 14.8% (14.2%-15.5%) and 9.5% (8.8%-10.1%), respectively, with no significant temporal trend. After adjusting on quinolone use, tetracycline use in the preceding month was significantly associated with nalidixic acid non-susceptibility (estimate [SD], 0.01 [0.007]; p-value, 0.04), but not with ciprofloxacin non-susceptibility (estimate [SD], 0.01 [0.009]; p-value, 0.23). Tetracycline use in the community may promote quinolone non-susceptibility in E. coli. Decreasing both tetracycline and quinolone use may be necessary to fight against the worldwide growth of quinolone resistance.

Indexed as

AdultAnti-Bacterial AgentsCiprofloxacinCommunity-Acquired InfectionsDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedNalidixic AcidRetrospective StudiesTetracyclineAnti-Bacterial AgentsCiprofloxacinNalidixic AcidTetracycline

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.